Free Trial
NASDAQ:LFCR

Lifecore Biomedical (LFCR) Stock Price, News & Analysis

Lifecore Biomedical logo
$7.76 +0.03 (+0.39%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$8.25 +0.49 (+6.31%)
As of 08/7/2025 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lifecore Biomedical Stock (NASDAQ:LFCR)

Key Stats

Today's Range
$7.49
$7.86
50-Day Range
$6.61
$8.78
52-Week Range
$3.68
$8.85
Volume
142,998 shs
Average Volume
136,726 shs
Market Capitalization
$287.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Moderate Buy

Company Overview

Lifecore Biomedical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
19th Percentile Overall Score

LFCR MarketRank™: 

Lifecore Biomedical scored higher than 19% of companies evaluated by MarketBeat, and ranked 855th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lifecore Biomedical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lifecore Biomedical has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lifecore Biomedical's stock forecast and price target.
  • Earnings Growth

    Earnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.91) to ($0.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lifecore Biomedical is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lifecore Biomedical is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lifecore Biomedical has a P/B Ratio of 20.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lifecore Biomedical's valuation and earnings.
  • Percentage of Shares Shorted

    7.60% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lifecore Biomedical has recently increased by 6.52%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lifecore Biomedical does not currently pay a dividend.

  • Dividend Growth

    Lifecore Biomedical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.60% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lifecore Biomedical has recently increased by 6.52%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Lifecore Biomedical has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Lifecore Biomedical this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Lifecore Biomedical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,650,266.00 in company stock.

  • Percentage Held by Insiders

    32.20% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lifecore Biomedical's insider trading history.
Receive LFCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter.

LFCR Stock News Headlines

Critical AI announcement set to ignite AI 2.0
Markets are jittery. Rallies fade. Sectors rotate overnight. And the true impact of new tariffs and policy shifts hasn’t even hit the data yet. That’s why smart traders are turning to a strategy built for exactly this kind of market—fast, simple, and designed to react to real price action, not predictions.
Lifecore Biomedical Insider Ups Holding During Year
See More Headlines

LFCR Stock Analysis - Frequently Asked Questions

Lifecore Biomedical's stock was trading at $7.43 at the beginning of 2025. Since then, LFCR shares have increased by 4.4% and is now trading at $7.76.

Lifecore Biomedical, Inc. (NASDAQ:LFCR) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.08. Lifecore Biomedical had a negative net margin of 35.90% and a negative trailing twelve-month return on equity of 551.09%.
Read the conference call transcript
.

Lifecore Biomedical's top institutional investors include GWN Securities Inc. (0.04%). Insiders that own company stock include Wynnefield Partners Small Cap and Paul Josephs.
View institutional ownership trends
.

Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lifecore Biomedical investors own include JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Visa (V).

Company Calendar

Today
8/07/2025
Last Earnings
8/07/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
5/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LFCR
CIK
1005286
Employees
690
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$6.00
Potential Upside/Downside
+3.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$12.01 million
Net Margins
-35.90%
Pretax Margin
-34.31%
Return on Equity
-551.09%
Return on Assets
-13.89%

Debt

Debt-to-Equity Ratio
66.36
Current Ratio
2.71
Quick Ratio
1.59

Sales & Book Value

Annual Sales
$128.26 million
Price / Sales
2.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.37 per share
Price / Book
20.97

Miscellaneous

Outstanding Shares
37,030,000
Free Float
25,103,000
Market Cap
$287.35 million
Optionable
Optionable
Beta
0.65
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:LFCR) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners